Kamilla W Miskowiak, Zacharias K Obel, Riccardo Gugliemo, Caterina Del Mar Bonnin, Christopher R Bowie, Vicente Balanzá-Martínez, Katherine E Burdick, Andre F Carvalho, Annemieke Dols, Katie Douglas, Peter Gallagher, Lars V Kessing, Beny Lafer, Kathryn E Lewandowski, Carlos López-Jaramillo, Anabel Martinez-Aran, Roger S McIntyre, Richard J Porter, Scot E Purdon, Ayal Schaffer, Paul R A Stokes, Tomiki Sumiyoshi, Ivan J Torres, Tamsyn E Van Rheenen, Lakshmi N Yatham, Allan H Young, Eduard Vieta, Gregor Hasler
BACKGROUND: Abnormalities in dopamine and norepinephrine signaling are implicated in cognitive impairments in bipolar disorder (BD) and attention-deficit hyperactivity disorder (ADHD). This systematic review by the ISBD Targeting Cognition Task Force therefore aimed to investigate the possible benefits on cognition and/or ADHD symptoms and safety of established and off-label ADHD therapies in BD. METHODS: We included studies of ADHD medications in BD patients, which involved cognitive and/or safety measures...
March 3, 2024: Bipolar Disorders